Who makes Debrisoquin?

Debrisoquin is developed by Hadassah Medical Organization.

What development phase is Debrisoquin in?

Debrisoquin is FDA-approved (marketed).

What is the generic name of Debrisoquin?

Debrisoquine is the generic (nonproprietary) name of Debrisoquin.

Last reviewed 2026-04-20 · How we verify

Debrisoquin (Debrisoquine)

Hadassah Medical Organization · FDA-approved active Small molecule Quality 15/100

At a glance

Generic name	Debrisoquine
Sponsor	Hadassah Medical Organization
Drug class	debrisoquine
Target	Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Debrisoquin CI brief — competitive landscape report
Debrisoquin updates RSS · CI watch RSS
Hadassah Medical Organization portfolio CI